[1]
S. Arora, MD, “A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain”, J of Opioid Management, vol. 10, no. 6, pp. 423–436, Nov. 2014.